Across its four current business areas, Wound Care, ORS, Gloves, and Antiseptics, the board has concluded that changing market dynamics, customer needs, and value drivers are best addressed by operating as two standalone companies, it states.

“We are making this move from a position of strength. Greater focus will allow both companies to move faster, invest with greater clarity, and respond more effectively to evolving customer needs,” adds Guillaume Joucla, Interim CEO of Mölnlycke.

Mölnlycke and Mölnlycke Surgical

The remaining Mölnlycke entity will comprise Wound Care and Antiseptics.

“Our ongoing assessment of Mölnlycke’s portfolio has highlighted the opportunity for two strong standalone companies, each with the focus, accountability, and resources to realize its full potential and be better positioned to create long-term value,” says Karl-Henrik Sundström, Chair of the Board of Directors at Mölnlycke.

In 2025, these businesses generated net sales of approximately EUR 1.3 billion and an EBITDA margin of approximately 38%. Mölnlycke Surgical will comprise ORS and Gloves. In 2025, these businesses generated net sales of approximately EUR 0.8 billion and an EBITDA margin of approximately 11%.

The intention is for both companies to operate as standalone portfolio companies under Patricia Industries’ ownership, with the separation expected to be completed during 2027, subject to customary approvals.